Search results
Author(s):
María Martin
Added:
2 years ago
Martin, María, et al. European Cardiology Review 2021; 16:e35. DOI:https://doi.org/10.15420/ecr.2021.09
View more
Author(s):
Elved B Roberts
,
Nicholas D Palmer
Added:
3 years ago
Late stent thrombosis has been a concern for interventional cardiologists since the early days of drug-eluting stent (DES) technology. Although the problem did not appear common, a series of angiographically documented late stent thromboses from the Thoraxcenter Rotterdam was published in 2004, sounding a cautionary, albeit non-alarmist, note.1 In 2005, a prospective observational cohort study of…
View more
Author(s):
Paul A Gurbel
,
David Kandzari
Added:
3 years ago
The rare but catastrophic occurrence of stent thrombosis, in particular 'late' stent thrombosis, in association with deployment of drug-eluting stents has focused attention on the adequacy of the current dual anti-platelet regimen of aspirin and clopidogrel. Stent thrombosis is due to multiple factors. These include, specific stent features (delayed healing or polymer hypersensitivity),…
View more
Author(s):
María Martin
,
Javier Cuevas
,
Helena Cigarrán
,
et al
Added:
2 years ago
Author(s):
Alberto Lorenzatti
,
Maria Luz Servato
Added:
3 years ago
Coronary artery disease (CAD) is the leading cause of death in most countries. Compelling evidence from epidemiological, genetic and clinical studies as well as experiments in animal models has unquestionably established that elevated concentrations of cholesterol (mainly transported by LDL particles) promote atherosclerotic lesions.1 Although statin-based lipid-lowering therapies have been shown…
View more
Author(s):
Jacques Machecourt
Added:
3 years ago
Drug-eluting stents (DES) have been recognised as a ‘breakthrough technology’ since 2003 due to their unique capacity to reduce clinical restenosis. The difference in restenosis rates, as assessed by angiography, was so large between DES and bare-metal stents (BMS) in the first trials – 0% versus 26% after six months in the first published trial (RAVEL) with the sirolimus-eluting stent (SES),1…
View more
Author(s):
Duk-Woo Park
Added:
1 year ago
In this short interview, Dr Duk-Woo Park (Asan Medical Center, KR) discusses the findings from the ADAPT-TAVR Randomized Clinical Trial (NCT03284827).
The trial investigated Edoxaban versus dual antiplatelet therapy for leaflet thrombosis and cerebral thromboembolism after TAVR.
Presented first at ACC.22, ADAPT-TAVR shows that the overall incidence of leaflet thrombosis on CT scans was less…
View more
Clinical Application of a Novel Self-expanding Coronary Stent in Acute Myocardial Infarction
Author(s):
Christian Spaulding
Added:
3 years ago
Article
Author(s):
Peter J Fitzgerald
,
Martin B Leon
Added:
3 years ago
An unintended consequence of the market success of drug-eluting stents has been a growing concern about their safety and safety-related costs. These devices have been so quickly and widely adopted that their market penetration already equals that of some of the most popular pharmaceutical drugs. Consequently, the absolute significance of even a low incidence of side effects becomes magnified by…
View more
Alex Spyropoulos
Job title: Professor
Author